Seattle Genetics Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 14,465 shares of Seattle Genetics stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $54.41, for a total transaction of $787,040.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Clay B. Siegall also recently made the following trade(s):

  • On Thursday, September 8th, Clay B. Siegall sold 31,269 shares of Seattle Genetics stock. The shares were sold at an average price of $50.08, for a total transaction of $1,565,951.52.
  • On Monday, August 22nd, Clay B. Siegall sold 23,381 shares of Seattle Genetics stock. The shares were sold at an average price of $46.59, for a total transaction of $1,089,320.79.
  • On Monday, August 8th, Clay B. Siegall sold 11,660 shares of Seattle Genetics stock. The shares were sold at an average price of $47.19, for a total transaction of $550,235.40.
  • On Wednesday, July 27th, Clay B. Siegall sold 4,042 shares of Seattle Genetics stock. The shares were sold at an average price of $45.20, for a total transaction of $182,698.40.

Seattle Genetics Inc. (NASDAQ:SGEN) opened at 53.09 on Thursday. The stock has a 50 day moving average of $51.78 and a 200-day moving average of $43.19. The company’s market capitalization is $7.46 billion. Seattle Genetics Inc. has a 12-month low of $26.02 and a 12-month high of $57.83.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings data on Tuesday, July 26th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The firm earned $95.40 million during the quarter, compared to the consensus estimate of $94.56 million. Seattle Genetics had a negative return on equity of 15.29% and a negative net margin of 27.21%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the company earned ($0.38) EPS. Equities analysts expect that Seattle Genetics Inc. will post ($1.00) earnings per share for the current year.

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Several equities analysts have weighed in on SGEN shares. Morgan Stanley assumed coverage on shares of Seattle Genetics in a report on Wednesday, September 7th. They set an “overweight” rating and a $60.00 price target on the stock. Leerink Swann reissued a “buy” rating and issued a $62.00 target price on shares of Seattle Genetics in a report on Friday, September 16th. Goldman Sachs Group Inc. downgraded shares of Seattle Genetics from a “neutral” rating to a “sell” rating in a report on Friday, September 16th. RBC Capital Markets reissued an “outperform” rating and issued a $62.00 target price (up previously from $55.00) on shares of Seattle Genetics in a report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price (up previously from $60.00) on shares of Seattle Genetics in a report on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $51.53.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Seattle Genetics by 37.5% in the second quarter. JPMorgan Chase & Co. now owns 3,595 shares of the company’s stock worth $145,000 after buying an additional 981 shares during the last quarter. First National Bank of Omaha purchased a new position in Seattle Genetics during the third quarter valued at $201,000. HighTower Advisors LLC purchased a new position in Seattle Genetics during the second quarter valued at $206,000. Carl Domino Inc purchased a new position in Seattle Genetics during the second quarter valued at $218,000. Finally, Levin Capital Strategies L.P. purchased a new position in Seattle Genetics during the second quarter valued at $218,000. 97.93% of the stock is owned by hedge funds and other institutional investors.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.